Navigation Links
Novogen Launches Joint Venture Aimed At Developing Drugs to Fight Ovarian Cancer
Date:11/6/2013

SYDNEY, Nov. 6, 2013 /PRNewswire/ -- Novogen Limited (Australian Securities Exchange: NRT and NASDAQ: NVGN), an Australian biotechnology company dedicated to developing drugs that provide long-term remission through the successful control of cancer stem cells, today announced a joint venture with Yale University dedicated to developing personalized approaches to chemotherapy to fight ovarian cancer.

The joint venture, which will be based near Yale's campus in New Haven, CT, will be known as CanTx, Inc. Novogen will own 85% of the new company and Novogen CEO Graham Kelly, PhD will be CEOoft the new joint venture as well. The CanTx Board will be comprised of directors representing both Novogen and Yale.

CanTx will assume responsibility for advancing Novogen's super-benzopyran drug technology into the clinic for the treatment of ovarian cancer. CanTx's first development candidate, designed to seek out cancer cells and deliver a payload of a Novogen drug that has been shown to be highly cytotoxic against ovarian cancer cells including ovarian cancer stem cells, is expected to enter clinical studies in 2014. The investigational product will be administered intra-peritoneally to women with ovarian cancer.

"There have been no new therapies for ovarian cancer in the last 30 years and a fresh approach is urgently needed," said Gil Mor, M.D., Ph.D., Professor of Obstetrics and Gynecology and Reproductive Science at Yale University School of Medicine. "Current chemotherapy unfortunately only does half the job. It is reasonably effective at killing the predominant somatic cancer cells, but by not killing the source of the cancer, the cancer stem cells, the cancer is highly likely to recur."

Dr. Mor, who will co-lead clinical development efforts for CanTx, is
'/>"/>

SOURCE Novogen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards
2. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
3. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
4. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
5. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
6. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
7. Neogen Launches Fully Quantitative Lateral Flow Test for DON
8. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
9. iHealth Lab Launches Personalized Web Portal to Store Your Vitals
10. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
11. Upsher-Smith Launches B-Nexa® Prescription Prenatal Vitamin With B Vitamins and Ginger for Nausea and Vomiting of Pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader in ... new Director of Product Strategy. In this role, Michelle will ... sub-teams to guide in the development of iLab products. Her ... maximum possible benefit to the scientific community by offering the ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Calif., July 22 CV Therapeutics,Inc. (Nasdaq: CVTX ... results for 2008 after the market closes on Thursday, ... at 5:00 p.m. EDT,2:00 p.m. PDT, on the company,s ... on to the Company,s website at, http://www.cvt.com and ...
... is bringing aboard Ashton S. Maaraba, a key Pharmacy, Pharmacy Services ... , ... (PRWEB) July 22, 2008 -- PharmaSmart International ... Ashton S. Maaraba, a key Pharmacy, Pharmacy Services & HBC industry ...
... U.S. Department of Energy,s Lawrence Berkeley National Laboratory (Berkeley ... performed the first scanning tunneling spectroscopy of graphene flakes ... latest in a series of surprising insights into the ... carbon: an unexpected gap-like feature in the energy spectrum ...
Cached Biology Technology:CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008 2Pharmasmart International Taps Top Executive Ashton Maaraba to Head Global Sales and Marketing 2A phonon floodgate in monolayer carbon 2A phonon floodgate in monolayer carbon 3A phonon floodgate in monolayer carbon 4A phonon floodgate in monolayer carbon 5
(Date:7/9/2014)... developed by researchers at the NIH,s National ... its collaborators to treat sickle cell disease ... business. The drug candidate, Aes-103, is the ... molecular mechanism of sickle cell disease. Baxter ... required for regulatory approval and commercialization. , ...
(Date:7/9/2014)... receptor antagonists can alleviate the symptoms of ... cognitive dysfunction and effectively scavenge amyloid beta ... (Aβ) vaccines reduced and eliminated Aβ deposition ... model, and significantly improved behavioral and cognitive ... First Affiliated Hospital of China Medical University, ...
(Date:7/9/2014)... inhabitants of the sea: tiny haptophytes of the type ... eye, when they are in bloom in spring, they ... on satellite images. "Together with other phytoplankton, Emiliania ... global photosynthesis output," states Prof. Dr. Georg Pohnert of ... the greenhouse gas carbon dioxide CO2 is ...
Breaking Biology News(10 mins):First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4Short circuit in the food web 2
... tropical parasitic disease that can lead to life-threatening heart ... than previously thought, according to research from The University ... for four years now, and this year the number ... professor of integrative biology and philosophy at The University ...
... Cincinnati, OH, October 6, 2011 -- Directly advertising food ... providers, and the American Academy of Pediatrics and the ... impact of advertising on children,s healthy food choices. ... Journal of Pediatrics explores the relationship between ...
... can ever know about long-gone creatures is what they ... resurrect actual specimens and compare their features with their ... Toronto biologists helping to create a seed bank that ... allowing them to measure evolution caused by global change. ...
Cached Biology News:Chagas disease may be a threat in South Texas, says researcher 2Study suggests children's food choices are affected by direct advertising and parental influence 2Seed time-capsule will aid study of plant evolution amid environmental change 2